AGIOS PHARMACEUTICALS, INC. (AGIO) Operating Income (Loss) USD 2012 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Agios Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2024.
  • Agios Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$92.1 M, a 1.61% decline year-over-year.
  • Agios Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$393 M, a 3.81% decline year-over-year.
  • Agios Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$391 M, a 0.63% decline from 2022.
  • Agios Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$389 M, a 2.81% decline from 2021.
  • Agios Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$378 M, a 12.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$393 M -$92.1 M -$1.46 M -1.61% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 -$391 M -$106 M -$7.11 M -7.16% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 -$384 M -$101 M -$9.81 M -10.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$375 M -$93.7 M +$3.94 M +4.04% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 -$379 M -$90.6 M +$10.5 M +10.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 -$389 M -$99.2 M +$5.66 M +5.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 -$395 M -$91.1 M +$62 K +0.07% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$395 M -$97.6 M -$6.42 M -7.04% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$388 M -$101 M -$9.93 M -10.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$378 M -$105 M -$12.4 M -13.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 -$366 M -$91.2 M -$10.9 M -13.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$355 M -$91.2 M -$7.96 M -9.56% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$347 M -$91.2 M -$4.19 M -4.81% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$343 M -$92.4 M +$13.5 M +12.7% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 -$357 M -$80.3 M +$28.8 M +26.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$385 M -$83.3 M +$30.6 M +26.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 -$416 M -$87 M +$10.5 M +10.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2019 -$426 M -$106 M -$9.57 M -9.94% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$417 M -$109 M -$9.9 M -9.98% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$407 M -$114 M -$40.9 M -56.1% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$366 M -$97.5 M -$3.47 M -3.69% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$362 M -$96.4 M -$6.23 M -6.91% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-19
Q3 2018 -$356 M -$99.2 M -$20.1 M -25.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-19
Q2 2018 -$336 M -$72.9 M +$11.7 M +13.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-19
Q1 2018 -$348 M -$94 M -$27 M -40.2% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-19
Q4 2017 -$321 M -$90.1 M -$32.7 M -57% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-14
Q3 2017 -$288 M -$79 M -$15.5 M -24.4% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-14
Q2 2017 -$273 M -$84.6 M -$28.1 M -49.8% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-14
Q1 2017 -$244 M -$67 M -$43.5 M -184% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-14
Q4 2016 -$201 M -$57.4 M -$16.5 M -40.4% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-14
Q3 2016 -$184 M -$63.5 M -$23 M -56.9% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-14
Q2 2016 -$161 M -$56.5 M -$24.3 M -75.7% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-14
Q1 2016 -$137 M -$23.6 M -$18.4 M -354% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-14
Q4 2015 -$119 M -$40.9 M -$14.2 M -53% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-16
Q3 2015 -$105 M -$40.5 M -$43.7 M -1362% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-16
Q2 2015 -$60.8 M -$32.1 M -$13.8 M -75.3% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-16
Q1 2015 -$47 M -$5.2 M +$7.09 M +57.7% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-16
Q4 2014 -$54.1 M -$26.7 M -$14.5 M -118% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-26
Q3 2014 -$39.6 M $3.21 M +$14.3 M Jul 1, 2014 Sep 30, 2014 10-K 2016-02-26
Q2 2014 -$53.9 M -$18.3 M -$9.8 M -115% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-26
Q1 2014 -$44.1 M -$12.3 M -$5.24 M -74.3% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-26
Q4 2013 -$38.9 M -$12.2 M -$5.74 M -88.4% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-24
Q3 2013 -$33.1 M -$11.1 M -$5.96 M -117% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-24
Q2 2013 -$27.2 M -$8.53 M -$2.4 M -39.2% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-24
Q1 2013 -$24.8 M -$7.05 M -$1.78 M -33.9% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-24
Q4 2012 -$23 M -$6.5 M Oct 1, 2012 Dec 31, 2012 10-K 2014-03-18
Q3 2012 -$5.11 M Jul 1, 2012 Sep 30, 2012 10-K 2014-03-18
Q2 2012 -$6.12 M Apr 1, 2012 Jun 30, 2012 10-K 2014-03-18
Q1 2012 -$5.26 M Jan 1, 2012 Mar 31, 2012 10-K 2014-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.